SCHEMBL3273469

SCHEMBL3273469

Nc1cc(Cl)c(F)cc1S(N)(=O)=O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 10/20 0.68
CA2 P00918 10/20 0.68
CA9 Q16790 7/20 0.68
CA4 P22748 6/20 0.68
CA12 O43570 5/20 0.68
CA6 P23280 5/20 0.68
CA5A P35218 5/20 0.68
CA7 P43166 5/20 0.68
CA14 Q9ULX7 5/20 0.68
CA5B Q9Y2D0 5/20 0.68
CA3 P07451 1/20 0.68
POLB P06746 1/20 0.46
APEX1 P27695 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
ALDH1A1 P00352 2/20 0.44
LMNA P02545 1/20 0.41
CYP2C9 P11712 1/20 0.41
CA13 Q8N1Q1 1/20 0.41
PTGES2 Q9H7Z7 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3778122 0.92 CA1 (0.62) CA1CA2CA9CA4CA12
SCHEMBL2777246 0.83 CA2 (0.46) CA1CA2CA9CA4CA12
SCHEMBL1807804 0.83 CA1 (0.79) CA1CA2CA9CA4CA12
SCHEMBL2777430 0.83 CA1 (0.54) CA1CA2CA9CA4CA12
SCHEMBL29376122 0.81 CA1 (1.00) CA1CA2CA9CA4CA12
SCHEMBL310205 0.81 CA1 (1.00) CA1CA2CA9CA4CA12
SCHEMBL30659050 0.81 CA1 (1.00) CA1CA2CA9CA4CA12
SCHEMBL2777121 0.79 CA2 (0.46) CA1CA2CA9CA4CA12
SCHEMBL20485809 0.79 CA1 (0.55) CA1CA2CA9CA4CA12
SCHEMBL1699945 0.77 CA1 (0.57) CA1CA2CA9CA4CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250360142-A1 NOVEL ATP-SENSITIVE POTASSIUM CHANNEL POTENTIATORS, THEIR PREPARATION AND USE RHYTHM PHARMACEUTICALS INC (US) 2025-11-27 US disclosed
EP-4605383-A1 NOVEL ATP-SENSITIVE POTASSIUM CHANNEL POTENTIATORS, THEIR PREPARATION AND USE Rhythm Pharmaceuticals, Inc. (US) 2025-08-27 EP disclosed
WO-2024086252-A1 NOVEL ATP-SENSITIVE POTASSIUM CHANNEL POTENTIATORS, THEIR PREPARATION AND USE RHYTHM PHARMACEUTICALS, INC. (US) 2024-04-25 WO disclosed
US-20100087496-A1 NOVEL CINNAMIC AMIDE DERIVATIVES USEFUL AS ION CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2010-04-08 US disclosed
EP-2121569-A2 NOVEL CINNAMIC AMIDE DERIVATIVES USEFUL AS ION CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2009-11-25 EP disclosed
WO-2008074755-A2 NOVEL CINNAMIC AMIDE DERIVATIVES USEFUL AS ION CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2008-06-26 WO disclosed
CN-1081633-C 1,2, 4-benzothiadiazine derivatives, method for preparing same and use thereof NOVO NORDISK AS (DK) 2002-03-27 CN disclosed
US-6242443-B1 1,2,4-benzothiadiazine derivatives, their preparation and use NOVO NORDISK AIS (DK) 2001-06-05 US disclosed
CN-1222910-A 1,2, 4-benzothiadiazine derivatives, method for preparing same and use thereof NOVO NORDISK AS (DK) 1999-07-14 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087496-A1 NOVEL CINNAMIC AMIDE DERIVATIVES USEFUL AS ION CHANNEL MODULATORS TRPV1, TRPA1, TRPM8 CA1 1200/4885CA2 216/4885CA9 3282/4885
US-20250360142-A1 NOVEL ATP-SENSITIVE POTASSIUM CHANNEL POTENTIATORS, THEIR PREPARATION AND USE KCNJ11, ATP1A2, ATP1A3 CA1 3276/4885CA2 647/4885CA9 2203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.